Source / episode info
- **Episode:**472
- **Title:**Divine Intervention Episode 472: Alpha-2 Receptors and the USMLEs (Step 1-3)
- **Published:**2023-07-27
- Source:Episode page
One-liner
This episode integrates {Alpha-2} receptor pharmacology, detailing how these inhibitory receptors regulate neurotransmitter release in the CNS and periphery, leading to high-yield clinical associations in glaucoma, opioid withdrawal, hypertension management (pheochromocytoma), and depression.
High-yield summary
- {Alpha-2} Receptor Mechanism: They are {G}_i-coupled receptors that decrease adenylate cyclase activity, resulting in less cAMP and thus a net reduction in protein phosphorylation.
- Glaucoma Management: {Alpha-2} agonists (e.g., Brimonidine) reduce sympathetic outflow to the eye, decreasing aqueous humor production and lowering intraocular pressure (IOP).
- Opioid Withdrawal: Opioids act on the -receptor ({G}_i), which decreases norepinephrine release; therefore, an {Alpha-2} agonist like Clonidine can treat withdrawal symptoms by mimicking this effect.
- Pheochromocytoma Crisis Management: Must administer a nonselective {Alpha-blocker} (e.g., Phenoxybenzamine) before any Beta-blocker to prevent life-threatening, unopposed {Alpha-1}-mediated vasoconstriction.
- Drug-Induced Lupus (DIL): Associated with {Methyl-dopa}, but the most common causes are Hydralazine and Procainamide (HP mnemonic).
- {Alpha-2} Agonists in Pregnancy: Preferred anti-hypertensives over older agents due to better fetal renal safety profile.
Learning objectives
- Describe the inhibitory (\text{G}_i) mechanism of \text{Alpha-2} receptors and its impact on cellular phosphorylation.
- Apply knowledge of \text{Alpha-2} agonists to manage glaucoma by reducing aqueous humor production.
- Understand the critical sequence of drug administration (alpha blocker -> beta blocker) in pheochromocytoma crisis management.
- Differentiate between the mechanisms of action for various anti-hypertensive agents used during pregnancy and in chronic hypertension.
- Recognize the clinical utility of \text{Alpha-2} agonists/antagonists in treating opioid withdrawal, ADHD, and depression.